| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDC34; UBCH3; UBE2R1; Ubiquitin-conjugating enzyme E2 R1; Ubiquitin-conjugating enzyme E2-32 kDa complementing; Ubiquitin-conjugating enzyme E2-CDC34; Ubiquitin-protein ligase R1 |
| Entrez GeneID | 997 |
| WB Predicted band size | Calculated MW: 27 kDa; Observed MW: 32 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of human Cdc34 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CDC34抗体的3篇参考文献，包含文献名称、作者及摘要内容概括：
1. **文献名称**：*The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme*
**作者**：Goebl, M. G., et al.
**摘要**：该研究首次克隆并鉴定了酵母CDC34基因，证明其编码的蛋白属于泛素结合酶(E2)家族，并参与细胞周期调控。研究中可能使用抗体验证CDC34蛋白的表达及功能，为后续泛素-蛋白酶体通路研究奠定基础。
2. **文献名称**：*Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27*
**作者**：Pagano, M., et al.
**摘要**：本文揭示了CDC34通过泛素-蛋白酶体通路调控p27蛋白降解的机制。研究中使用CDC34抗体进行免疫沉淀和Western blot实验，证明CDC34在细胞周期进程中促进p27的泛素化及降解。
3. **文献名称**：*Mechanism of lysine 48-linked ubiquitin-chain synthesis by the cullin-RING ubiquitin-ligase SCF-Cdc34*
**作者**：Petroski, M. D., & Deshaies, R. J.
**摘要**：该研究阐明了SCF-Cdc34复合物催化K48多聚泛素链形成的分子机制。通过CDC34抗体进行体外酶活实验和结构分析，揭示了其与底物结合及泛素转移的具体步骤。
这些文献涵盖了CDC34的基础功能、在细胞周期调控中的作用及分子机制研究，均涉及CDC34抗体的实验应用(如蛋白检测、互作分析等)。如需更多应用类文献，可进一步检索特定疾病模型(如癌症)中的CDC34抗体使用案例。
The CDC34 antibody is a crucial tool in studying the ubiquitin-proteasome system, particularly focusing on the CDC34 (Cell Division Cycle 34) protein, a member of the E2 ubiquitin-conjugating enzyme family. CDC34 plays a central role in catalyzing the transfer of ubiquitin to substrate proteins, a process essential for protein degradation, cell cycle regulation, and DNA repair. It is best known for its partnership with the SCF (SKP1-CUL1-F-box protein) E3 ligase complex, which targets key cell cycle regulators like cyclin-dependent kinase inhibitors (e.g., p27) for proteasomal degradation, enabling G1/S phase transition.
Research on CDC34 antibodies has advanced understanding of its involvement in cellular proliferation, oncogenesis, and therapeutic resistance. Dysregulation of CDC34 is linked to cancers, neurodegenerative diseases, and immune disorders due to aberrant protein turnover. These antibodies are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to detect CDC34 expression levels, localization, and interaction networks in experimental models.
Additionally, CDC34 antibodies aid in exploring post-translational modifications and substrate specificity, offering insights into drug development targeting ubiquitination pathways. Their specificity and reliability make them indispensable in both basic research and translational studies aiming to modulate ubiquitin-dependent processes in disease contexts.
×
